There’s a new nose-spray flu vaccine. Should your kids get it?
A new needle-free flu vaccine, FluMist, is now available in Australia for children aged two to 18, offering an alternative to traditional injections. The nasal spray vaccine is already used in the US and Europe and is designed to improve flu vaccination rates among children, who are particularly vulnerable to influenza. While it is free for young children in some states, others must pay out of pocket, and its effectiveness is supported by a meta-analysis of 19 clinical trials.
- ▪FluMist is a needle-free influenza vaccine available for children aged two to 18 in Australia.
- ▪The vaccine is administered as a nasal spray and does not require deep inhalation.
- ▪It is free for children under five in NSW, Queensland, and South Australia, but costs $49.95 elsewhere, including for all children in Victoria.
- ▪A 2024 meta-analysis of 19 randomised-controlled trials compared FluMist's effectiveness to the standard flu shot.
- ▪Australia is receiving the vaccine now because AstraZeneca has developed a southern hemisphere-specific version.
Sydney Morning Herald publishes from Australia and files mainly under world. We currently carry 3,705 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Sydney Morning Herald |
| Canonical URL | https://www.smh.com.au/healthcare/there-s-a-new-nose-spray-flu-vaccine-should-your-kids-get-it-20260428-p5zrlj.html?ref=rss&utm_medium=rss&utm_source=rss_feed |
| Publication time | Tue, 28 Apr 2026 19:30:00 +1000 |
| Retrieval time | 2026-04-28T09:34:15.365Z |
| Last seen | 2026-04-28T09:34:15.365Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | hCkutda55d50 |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","dateModified":"2026-04-28T09:30:00Z","datePublished":"2026-04-28T09:30:00Z","description":"With flu season almost upon us, it’s time to get vaccinated. And for the first time, there’s more than one option available.","headline":"There’s a new nose-spray flu vaccine. Should your kids get it?","keywords":"Healthcare, Analysis, Just in Age, Flu season","author":[{"@type":"Person","name":"Liam Mannix","jobTitle":"National Science…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Sydney Morning Herald.